OliX PharmaceuticalsInc Asset Resilience Ratio

Latest as of June 2026: 37.46%

OliX PharmaceuticalsInc asset resilience ratio. OliX PharmaceuticalsInc (226950) has an Asset Resilience Ratio of 37.46% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 226950 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩102.67 Billion
≈ $69.58 Million USD Cash + Short-term Investments

Total Assets

₩274.07 Billion
≈ $185.73 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of OliX PharmaceuticalsInc (2016–2025)

Asset resilience ratio of OliX PharmaceuticalsInc from 2016 to 2025. This chart shows how OliX PharmaceuticalsInc's Asset Resilience Ratio has changed over time. Read 226950 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down OliX PharmaceuticalsInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of OliX PharmaceuticalsInc.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩102.67 Billion 37.46%
Total Liquid Assets ₩102.67 Billion 37.46%

Asset Resilience Insights

  • Very High Liquidity: OliX PharmaceuticalsInc maintains exceptional liquid asset reserves at 37.46% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

OliX PharmaceuticalsInc Industry Peers by Asset Resilience Ratio

Compare OliX PharmaceuticalsInc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Abivax SA
PA:ABVX
Biotechnology 2.58%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Disc Medicine Inc.
NASDAQ:IRON
Biotechnology 84.22%
Alpha Tau Medical Ltd
NASDAQ:DRTS
Biotechnology 65.79%
Galapagos N.V.
AS:GLPG
Biotechnology 86.45%

OliX PharmaceuticalsInc Asset Resilience Ratio by Year (2016–2025)

OliX PharmaceuticalsInc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for OliX PharmaceuticalsInc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 64.57% ₩126.15 Billion
≈ $85.49 Million
₩195.37 Billion
≈ $132.40 Million
+52.61pp
2024-12-31 11.96% ₩8.52 Billion
≈ $5.78 Million
₩71.25 Billion
≈ $48.28 Million
-1.59pp
2023-12-31 13.55% ₩13.93 Billion
≈ $9.44 Million
₩102.83 Billion
≈ $69.68 Million
-33.09pp
2022-12-31 46.64% ₩61.87 Billion
≈ $41.93 Million
₩132.65 Billion
≈ $89.90 Million
-10.77pp
2021-12-31 57.41% ₩49.76 Billion
≈ $33.72 Million
₩86.67 Billion
≈ $58.74 Million
-29.27pp
2020-12-31 86.68% ₩68.11 Billion
≈ $46.16 Million
₩78.58 Billion
≈ $53.25 Million
+42.54pp
2019-12-31 44.14% ₩19.95 Billion
≈ $13.52 Million
₩45.21 Billion
≈ $30.64 Million
-7.65pp
2018-12-31 51.79% ₩28.81 Billion
≈ $19.53 Million
₩55.64 Billion
≈ $37.70 Million
-0.51pp
2017-12-31 52.30% ₩11.32 Billion
≈ $7.67 Million
₩21.64 Billion
≈ $14.67 Million
-10.30pp
2016-12-31 62.60% ₩9.48 Billion
≈ $6.43 Million
₩15.15 Billion
≈ $10.27 Million
--
pp = percentage points

About OliX PharmaceuticalsInc

KQ:226950 Korea Biotechnology
Market Cap
$1.13 Billion
₩1.66 Trillion KRW
Market Cap Rank
#8161 Global
#201 in Korea
Share Price
₩81800.00
Change (1 day)
+10.39%
52-Week Range
₩74100.00 - ₩207000.00
All Time High
₩207000.00
About

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more